Access to cancer medications in low- and middle-income countries
- 9 April 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 10 (6), 314-322
- https://doi.org/10.1038/nrclinonc.2013.55
Abstract
Major breakthroughs have been realized in controlling cancer in the past five decades. However, for patients in low- and middle-income countries (LMICs), many of these advances are nothing but an aspiration and hope for the future. Indeed, the greatest challenge we face in oncology today is how to reconcile small, incremental and significant improvements in the management of cancer with the exponentially increasing costs of new treatments. Emerging economies are attempting to address this important issue of access to cancer medications. In this Review, we examine how LMICs are using generic and biosimilar drugs, expanding participation in clinical trials, implementing universal health-care schemes to pool resources, and using compulsory licensing schemes as well as increasing multiple-stakeholder public-private partnerships to increase access to cancer medications for their citizens. Any truly effective programme will require multiple stakeholder involvement-including governments, industry and civil society-to address the issue of access to medication. Only with the creation of a global entity to fight cancer that is supported by a global fund-for example, in the mould of the GAVI alliance and the International Finance Facility for Immunization-will we truly be able to improve cancer care in LMICs and drive down the high mortality rates in these regions.Keywords
This publication has 23 references indexed in Scilit:
- Performance-based financing at the Global Fund to Fight AIDS, Tuberculosis and Malaria: an analysis of grant ratings and funding, 2003–12The Lancet. Global Health, 2013
- Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in IndiaAnnals Of Oncology, 2013
- Government use licenses in Thailand: an assessment of the health and economic impactsGlobalization and Health, 2011
- Bending the Cost Curve in Cancer CareNew England Journal of Medicine, 2011
- Declining Death Rates Reflect Progress against CancerPLOS ONE, 2010
- Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biology & Therapy, 2010
- Ethical and Scientific Implications of the Globalization of Clinical ResearchNew England Journal of Medicine, 2009
- Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side EffectsJournal of Law, Medicine & Ethics, 2009
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLoS Medicine, 2006